Please login to the form below

Not currently logged in
Email:
Password:

VC firm expands team, appoints Genzyme and Lilly veterans

New roles for James Geraghty, Steven Paul, Daniel Lynch and John Maraganore

Third Rock Steven PaulUS venture capital company Third Rock Ventures has expanded its team by appointing a number of industry heavyweights.

The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies.

James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while the former president of Lilly Research Laboratories, Steven Paul (pictured right), takes on an increased role at Third Rock with a position as a venture partner.

Third Rock Daniel LynchAlso joining Third Rock as venture partners are Daniel Lynch (pictured right), a former CEO of ImClone Systems, and Alnylam's CEO John Maraganore. 

Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated - through decades of experience - their ability to integrate science and business.

“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”

15th May 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics